Ionis Pharmaceuticals annual gross margin
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ionis Pharmaceuticals Gross Margin Growth & History (IONS)
Ionis Pharmaceuticals's gross margin was 98.31% for fiscal 2025.
View full Ionis Pharmaceuticals company overviewIonis Pharmaceuticals annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 98.31% | −0.10 pp |
| 2024 | 2024-12-31 | 98.41% | −0.43 pp |
| 2023 | 2023-12-31 | 98.84% | +1.24 pp |
| 2022 | 2022-12-31 | 97.60% | −1.07 pp |
| 2021 | 2021-12-31 | 98.66% | +0.30 pp |
| 2020 | 2020-12-31 | 98.36% | −1.25 pp |
| 2019 | 2019-12-31 | 99.61% | −0.09 pp |
| 2018 | 2018-12-31 | 99.70% | −0.30 pp |
| 2017 | 2017-12-31 | 100.00% | 0.00 pp |
| 2016 | 2016-12-31 | 100.00% | — |
Ionis Pharmaceuticals quarterly gross margin
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 98.98% | −0.10 pp |
| Q1 2026 | 2026-03-31 | 98.79% | −0.10 pp |
| Q4 2025 | 2025-12-31 | 96.09% | −2.22 pp |
| Q3 2025 | 2025-09-30 | 98.51% | −0.69 pp |
| Q2 2025 | 2025-06-30 | 99.08% | +0.93 pp |
| Q1 2025 | 2025-03-31 | 98.89% | +0.69 pp |
| Q4 2024 | 2024-12-31 | 98.31% | −0.75 pp |
| Q3 2024 | 2024-09-30 | 99.20% | +0.72 pp |
| Q2 2024 | 2024-06-30 | 98.15% | −0.50 pp |
| Q1 2024 | 2024-03-31 | 98.20% | −0.77 pp |
| Q4 2023 | 2023-12-31 | 99.06% | +1.48 pp |
| Q3 2023 | 2023-09-30 | 98.48% | −0.57 pp |
| Q2 2023 | 2023-06-30 | 98.65% | +2.20 pp |
| Q1 2023 | 2023-03-31 | 98.97% | +1.91 pp |
| Q4 2022 | 2022-12-31 | 97.57% | −1.92 pp |
| Q3 2022 | 2022-09-30 | 99.05% | +1.37 pp |
| Q2 2022 | 2022-06-30 | 96.45% | −1.19 pp |
| Q1 2022 | 2022-03-31 | 97.06% | −0.63 pp |
| Q4 2021 | 2021-12-31 | 99.49% | +0.63 pp |
| Q3 2021 | 2021-09-30 | 97.69% | −0.39 pp |
| Q2 2021 | 2021-06-30 | 97.65% | −0.28 pp |
| Q1 2021 | 2021-03-31 | 97.69% | −0.40 pp |
| Q4 2020 | 2020-12-31 | 98.86% | −0.93 pp |
| Q3 2020 | 2020-09-30 | 98.07% | −1.35 pp |
| Q2 2020 | 2020-06-30 | 97.93% | −1.24 pp |
| Q1 2020 | 2020-03-31 | 98.09% | −1.56 pp |
| Q4 2019 | 2019-12-31 | 99.80% | +0.74 pp |
| Q3 2019 | 2019-09-30 | 99.42% | −0.58 pp |
| Q2 2019 | 2019-06-30 | 99.17% | −0.83 pp |
| Q1 2019 | 2019-03-31 | 99.65% | −0.35 pp |
| Q4 2018 | 2018-12-31 | 99.05% | — |
| Q3 2018 | 2018-09-30 | 100.00% | — |
| Q2 2018 | 2018-06-30 | 100.00% | — |
| Q1 2018 | 2018-03-31 | 100.00% | — |
Ionis Pharmaceuticals gross margin trends
Over the last five fiscal years, Ionis Pharmaceuticals's gross margin decreased from 98.36% to 98.31%, a change of −0.05 percentage points. The latest reported quarter, Q2 2026, shows 98.98%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ionis Pharmaceuticals source filings ↗Community posts
Roche quantifies proteinuria reduction for Ionis-licensed sefaxersen
Ionis ($IONS) reported new detailed results from partner Roche’s Phase 3 IMAgINATION trial of sefaxersen in IgA nephropathy. The investigational monthly injection reduced urine protein-to-creatinine ratio by 43.1% versus placebo at 37 weeks ...
